ALK and schwannoma: HEI193 cells (NF2-null, derived from a schwannoma of an NF2 patient), SC4 cells (Nf2-null mouse cells) and hSC2λ-shNF2 cells (hSC2λ cells – immortalized normal human Schwann cells with stable knockdown of NF2) were treated with crizotinib (PF-2341066), a FDA approved drug that is a potent inhibitor of MET, ALK and Ros-1 [11].